Study of APD421 as PONV Treatment (Prior Prophylaxis)

Postoperative Nausea and Vomiting Clinical Trial

Official title:

Randomised, Double-blind, Placebo-controlled Study of APD421 (Amisulpride for IV Injection) as Treatment of Established Post-operative Nausea and Vomiting, in Patients Who Have Had Prior Prophylaxis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02646566
• Other study ID #: DP10019
• Status: Completed
• Phase: Phase 3
• Start date: March 2016
• Est. completion date: January 2017

Study information

• Verified date: January 2019
• Source: Acacia Pharma Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless, dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established PONV, in patients who have had prior PONV prophylaxis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 705
• Est. completion date: January 2017
• Est. primary completion date: January 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Male or female patients = 18 years of age

• Provision of written informed consent

• Patients scheduled to undergo elective surgery (open or laparoscopic technique) under general anaesthesia (other than total intravenous anaesthesia with propofol) expected to last at least one hour from induction of anaesthesia to extubation

• Patients judged by the investigator to have a moderate or high risk of experiencing PONV. In forming this judgment, investigators should pay particular attention to risk factors such as a past history of PONV and/or motion sickness; habitual non-smoking status; female sex; and likely use of opioid analgesia post-operatively.

• For females of child-bearing potential: ability and willingness to use a highly effective form of contraception (as defined in ICH M3 guidance, e.g., abstinence from sexual intercourse, surgical sterilisation (of subject or partner), combined oral contraceptive pill, a double-barrier method of contraception such as either an intra-uterine device (IUD) or an occlusive cap with spermicide, in conjunction with partner's use of a condom, or any other method or combination of methods with a failure rate generally considered to be <1% per year) between the date of screening and at least 48 hours after administration of study drug

• In order to be eligible for randomisation, subjects must also:

(i) have experienced a first episode of PONV not more than 24 hours after the end of their operation (wound closure) and prior to discharge from hospital ("qualifying PONV episode"), for which they have not already received any anti-emetic treatment; and (ii) not have received any dopamine-antagonist agent likely to prevent or treat nausea or vomiting (given as prophylaxis or otherwise) in the period from 24 hours prior to the start of their operation up to the time of the qualifying PONV episode.

Exclusion Criteria:

• Patients scheduled to undergo transplant surgery or any surgery where post-operative emesis may pose a significant danger to the patient

• Patients planned to receive only a local anaesthetic and/or regional neuraxial (intrathecal or epidural) block

• Patients who have received APD421 active ingredient for any indication within the last 2 weeks

• Patients who are allergic to APD421 active ingredient or any of the excipients of APD421

• Patients with a significant, ongoing history of vestibular disease or dizziness

• Patients with a known prolactin-dependent tumour (e.g. pituitary gland prolactinoma or breast cancer) or phaeochromocytoma.

• Patients with documented or suspected alcohol or substance abuse within the past 6 months.

• Patients with direct or indirect evidence of clinically significant hypokalaemia, such as a serum potassium level < 3.0 mmol/L.

• Patients who have received in the post-operative period, and prior to receiving study drug, any medication with a substantial risk of inducing torsades de pointes, including Class Ia antiarrhythmic agents such as quinidine, disopyramide, procainamide; Class III antiarrhythmic agents such as amiodarone and sotalol; and other medications such as bepridil, cisapride, thioridazine, methadone, IV erythromycin, IV vincamine, halofantrine, pentamidine, sparfloxacin, etc.

• Patients who have a documented, clinically significant cardiac arrhythmia or congenital long QT syndrome.

• Patients who are pregnant or breast feeding.

• Patients being treated with levodopa.

• Patients diagnosed with Parkinson's disease.

• Patients who have received emetogenic anti-cancer chemotherapy in the previous 4 weeks.

• Patients with a history of epilepsy.

• Any other concurrent disease or illness that, in the opinion of the investigator makes the patient unsuitable for the study.

• Patients who have previously participated in this study or who have participated in another interventional clinical study involving pharmacological therapy within the previous 28 days (or longer exclusion period, if required by national or local regulations).

• Where local laws/regulations require: patients under legal protection.

Related Conditions & MeSH terms

• Nausea
• Postoperative Nausea and Vomiting
• Vomiting

Intervention

Drug:
• APD421

• Placebo

Locations

Country	Name	City	State
France	CHU de Hautepierre	Strasbourg
Germany	HELIOS Klinikum Aue	Aue
Germany	Universität Heidelberg	Heidelberg
Germany	Philipps University	Marburg
United States	Ohio State University	Columbus	Ohio
United States	Duke University Medical Center	Durham	North Carolina
United States	Jackson Memorial Hospital	Miami	Florida
United States	Wake Forest University School of Medicine	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Acacia Pharma Ltd

Countries where clinical trial is conducted

United States,  France,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Complete Response (Success of Initial PONV Treatment)	The primary efficacy variable was the dichotomous variable: success or failure of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) from 30 minutes* to 24 hours after administration of study medication and no administration of anti-emetic rescue medication at any time in the 24-hour period after administration of study medication.	0-24 hours after administration of study medication
Secondary	Number of Participants With Complete Response 0-2 Hrs	Success of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) from 30 minutes* to 2 hours after administration of study medication and no administration of anti-emetic rescue medication at any time in the 2-hour period after administration of study medication.	0-2 hours after administration of study medication
Secondary	Number of Participants With Complete Response 0-4 Hrs	Success of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) from 30 minutes* to 4 hours after administration of study medication and no administration of anti-emetic rescue medication at any time in the 4-hour period after administration of study medication.	0-4 hours after administration of study medication
Secondary	Number of Participants With Complete Response 0-6 Hrs	Success of initial PONV treatment, where success is defined as no emetic episodes (vomiting or retching) from 30 minutes to 6 hours after administration of study medication and no administration of anti-emetic rescue medication at any time in the 6-hour period after administration of study medication.	0-6 hours after administration of study medication
Secondary	Time to Treatment Failure	Time to first violation of the criteria for complete response	0-24 hours after study drug administration
Secondary	Number of Patients With Incidence of Emesis	Number of patients experiencing vomiting or retching during the time period from 30 minutes to 24 hours after administration of study medication	30 mins to 24 hours after study drug administration
Secondary	Number of Patients Receiving Rescue Medication	Number of patients receiving pre-specified anti-emetic rescue medication at any time in the 24 hours post-treatment period	0-24 hours after study drug administration
Secondary	Number of Patients With an Incidence of Significant Nausea	Number of patients with nausea score =4 on an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea, therefore higher value is worse outcome) during the time period from 30 minutes to 24 hours after administration of study medication.	30 mins to 24 hours after study drug administration
Secondary	Number of Patients With an Incidence of Nausea	Number of patients with nausea score =1 on an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea, therefore higher value is worse outcome) during the time period from 30 minutes to 24 hours after administration of study medication.	30 mins to 24 hours after drug administration
Secondary	Maximum Severity of Nausea	Highest recorded nausea score on an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea, therefore higher value is worse outcome) during the time period from 30 minutes to 24 hours after administration of study medication.	30 mins to 24 hours after study drug administration
Secondary	Evolution Score of Nausea (0-180 Mins)	The evolution score of nausea was calculated as the area under the curve (AUC) of the nausea scores on a scale 0-10 (where 0 is no nausea and 10 is the worst nausea imaginable) obtained at five pre-planned time points: pre-dose (0-min), and 5, 15 and 30 minutes and 2 hours after administration of study medication, as well as any spontaneously reported episodes of nausea during the time period, plotted against time. A higher score represents a worse outcome.	0-180 minutes after study drug administration